Merck News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

07.03.22	DGAP-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung (EQS Group)
07.03.22	DGAP-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung (EQS Group)
25.02.22	DGAP-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung (EQS Group)
17.02.22	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
16.02.22	DGAP-AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
16.02.22	DGAP-AFR: Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG (EQS Group)
16.02.22	DGAP-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements (EQS Group)
16.02.22	DGAP-AFR: Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen (EQS Group)
11.02.22	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.02.22	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
18.01.22	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
28.12.21	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
23.12.21	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
23.12.21	DGAP-DD: Merck KGaA deutsch (EQS Group)
23.12.21	DGAP-DD: Merck KGaA english (EQS Group)
03.12.21	DGAP-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
17.05.21	Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity (PR Newswire)
16.03.21	Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire)
16.03.21	Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer (PR Newswire)
25.02.21	New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-treated RMS Patients Mount Protective Antibody Response to Common Vaccines (PR Newswire)
27.11.20	European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations (PR Newswire)
09.11.20	Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics (PR Newswire)
06.10.20	Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis (PR Newswire)
14.09.20	Merck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020 (PR Newswire)
11.09.20	New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety (PR Newswire)
10.09.20	Merck Announces Positive Phase II Results for Investigational Sonelokinab (M1095) in Patients with Moderate to Severe Chronic Plaque-Type Psoriasis (PR Newswire)
03.09.20	Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis (PR Newswire)
13.07.20	Stephan Sieber Awarded € 1 Million Future Insight Prize 2020 by Merck (PR Newswire)
28.05.20	Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS (PR Newswire)
19.05.20	Merck Foundation Announce 'Stay at Home' Media Recognition Awards for Latin American Countries (PR Newswire)
14.05.20	/C O R R E C T I O N -- EMD Serono/ (PR Newswire)
14.05.20	Breakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020 (PR Newswire)
14.05.20	Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 (PR Newswire)
30.04.20	Data From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care (PR Newswire)
03.03.20	/DISREGARD RELEASE: Merck KGaA, Darmstadt, Germany/ (PR Newswire)
02.03.20	ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) (PR Newswire)
02.03.20	ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) (PR Newswire)
20.11.19	Merck KGaA, Darmstadt, Germany, Announces Orphan Drug Designation for Investigational Therapy Tepotinib in Patients with NSCLC Harboring MET Gene Alterations (PR Newswire)
28.10.19	European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma (PR Newswire)
27.09.19	New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019 (PR Newswire)
23.09.19	New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care (PR Newswire)
23.09.19	New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care (PR Newswire)
20.09.19	CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma (PR Newswire)
11.09.19	Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations (PR Newswire)
11.09.19	Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations (PR Newswire)
09.09.19	Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019 (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
16:02		S&P 500-Titel Colgate-Palmolive-Aktie: So viel hätten Anleger an einem Colgate-Palmolive-Investment von vor 5 Jahren verdient